skyrizi
abbvie limited - risankizumab 60 mg/ml - concentrate for infusion - 600 mg/10ml - active: risankizumab 60 mg/ml excipient: glacial acetic acid polysorbate 20 sodium acetate trihydrate trehalose dihydrate water for injection - skyrizi is indicated for the treatment of moderate to severe active crohn's disease in patients 16 years of age and older, who have an inadequate response, a lost response, an intolerance or a contra-indication to either conventional or biologic therapy.
chirocaine 1.25 mg/ml solution for infusion
abbvie limited - levobupivacaine hydrochloride - solution for infusion - 1.25 milligram(s)/millilitre - amides; levobupivacaine
sevorane 100% v/v inhalation gas
abbvie limited - sevoflurane - inhalation vapour, liquid - 100 percent volume/volume - halogenated hydrocarbons; sevoflurane
alphagan 0.2% w/v (2 mg/ml) eye drops, solution
abbvie limited - brimonidine tartrate - eye drops, solution - sympathomimetics in glaucoma therapy1); brimonidine
alphagan 0.2% w/v (2 mg/ml) eye drops, solution
abbvie limited citywest business campus, dublin 24, ireland - eye drops, solution - brimonidine tartrate 2 mg/ml - ophthalmologicals
moderiba
abbvie limited - ribavirin - film coated tablet - 400 milligram - ribavirin
moderiba
abbvie limited - ribavirin - film coated tablet - 600 milligram - ribavirin
moderiba
abbvie limited - ribavirin - film coated tablet - 200 milligram - ribavirin
sevorane 100% v/v inhalation gas
abbvie limited citywest business campus, dublin 24, ireland - sevoflurane - inhalation gas - sevoflurane 100 % (v/v) - anesthetics
relestat, 0.5 mg/ml, eye drops, solution
abbvie limited - epinastine hydrochloride - eye drops, solution - other antiallergics; epinastine